Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 14Terminated 2

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adrenocortical Carcinoma 1

Interventions

Cyclophosphamide 389Carboplatin 343Gemcitabine 331pembrolizumab 328Cisplatin 327Paclitaxel 294Radiotherapy 291Docetaxel 285Bevacizumab 249Rituximab 233Capecitabine 221Nivolumab 218Dexamethasone 205Fluorouracil 189fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 133Bortezomib 129fludarabine phosphate 128Cetuximab 126Lenalidomide 125Filgrastim 119Erlotinib Hydrochloride 119Temozolomide 111Radiosurgery 110

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Interventional × Suramin × Clear all
NCT01038752 2015-05-21

Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer

Optimum Therapeutics, LLC

Phase 2 Terminated
14 enrolled 10 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00002921 2012-10-05

S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery

SWOG Cancer Research Network

Phase 2 Terminated
13 enrolled
Endocrine

Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡